Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

Motzer, R.; Tannir, N.; McDermott, D.; A. Frontera, O.; Melichar, B.; Choueiri, T.; Plimack, E.; Barthélémy, P.; Porta, C.; George, S.; Powles, T.; Donskov, F.; Neiman, V.; Kollmannsberger, C.; Salman, P.; Gurney, H.; Hawkins, R.; Ravaud, A.; Grimm, M.; Bracarda, S.; Barrios, C.; Tomita, Y.; Castellano, D.; Rini, B.; C. Chen, Allen; Mekan, Sabeen; McHenry, B.; Wind-Rotolo, M.; Doan, J.; Sharma, Padmanee; Hammers, H.; Escudier, B.

doi:10.1056/NEJMoa1712126

Public

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

Shared by NobleBlocks on Mar 21, 2018 • 12:00 AM UTC

Authors:

R. Motzer

N. Tannir

D. McDermott

Abstract

BACKGROUND Nivolumab plus ipilimumab produced objective responses in patients with advanced renal‐cell carcinoma in a pilot study. This phase 3 trial compared nivolumab plus ipilimumab with sunitinib for previously untreated clear‐cell advanced renal‐cell carcinoma. METHODS We randomly assigned adul...

Subject

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!